To Get Full Access :

Blujepa

Blujepa treats uncomplicated urinary tract infections in females and adolescents with more than 12 years and more than or equal to 40 kg. It’s an oral antibiotic in a new class that combats common UTI bacteria and tackles antibiotic resistance.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Gepotidacin
  • Innovator :

    GLAXOSMITHKLINE LLC
  • Approval Date :

    25-Mar-25
  • NCE-1 Date :

    25-Mar-29
  • NCE Date :

    25-Mar-30
  • Dosage Form :

    Oral Tablet
  • Strength :

    EQ 750MG BASE
  • Therapeutic Category :

    Antibiotic
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    52
  • 2026 :

    167
  • 2027 :

    253
  • 2028 :

    345
  • 2029 :

    427
  • 2030 :

    497
  • 2031 :

    567
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?